Compositions and method for reducing virulence of microorganisms
The present disclosure relates to compositions and methods for reducing virulence of microorganisms. In particular, the present invention provides HMGB1 and variants and mimetics thereof for use in reducing virulence of microorganisms (e.g., in disease).
1. A method of treating or preventing microbial virulence in a subject suffering from decreased high mobility group box 1 (HMGB1) protein levels and/or a deficiency in HMGB1 function, the method comprising:
identifying decreased HMGB1 protein levels and/or a deficiency in HMGB1 function in the subject; and
administering a composition comprising an HMGB1 polypeptide or variant or fragment thereof and a pharmaceutically acceptable carrier to the subject, wherein said administering prevents or treats microbial virulence in said subject.
2. The method of claim 1 , wherein said microbe is a bacteria.
3. The method of claim 1 , wherein said HMGB1 polypeptide or variant or fragment thereof is conjugated to a drug.
4. The method of claim 3 , wherein said drug is an antimicrobial drug.
5. The method of claim 1 , wherein the subject further suffers from a chronic inflammatory disease, an infectious disease, a metabolic disease, or a cancer.
6. The method of claim 5 , wherein the subject suffers from a disease selected from the group consisting of inflammatory bowel disease, rheumatoid arthritis, non-alcoholic fatty liver disease, type II diabetes, urinary tract infection, colorectal cancer, and sepsis.
7. The method of claim 1 , wherein said HMGB1 polypeptide or variant or fragment thereof binds to the motif [S/T]-x-E-x-P in a microbial protein.
8. The method of claim 1 , wherein said HMGB1 polypeptide or variant or fragment thereof binds to E. coli FimH protein.
9. The method of claim 1 , wherein said HMGB1 polypeptide or variant or fragment thereof comprises at least one amino acid change relative to wild type HMGB1.